The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
Open accessAbstract
PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic efficacy of multiple mAbs targeting plasma membrane receptors involved in oncogenesis stems (at least in part) from their ability to bridge malignant cells and immune effector cells expressing Fc gamma receptors (Fc g Rs), culminating in antibody-dependent cellular cytotoxicity (ADCC) (Ferris et al., 2010).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Ferris et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,687
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112
Research works printed but not linked: 9
- Abes R, Blood
- Reilly RT, 2001, Cancer Res, 61, 880
- Sharafanski M, Head and Neck
- Valentini AM, 2008, Curr Opin Mol Ther, 10, 124
- Zhao WP, 2009, Oncol Rep, 21, 1405
- Whiteside TL, 1996, Anticancer Res, 16, 2357
- Ugurel S, 2002, Onkologie, 25, 129
- Li D, 2002, Cancer Res, 62, 4023
- 10.1158/1078-0432.CCR-05-2750 · DOI
Cited by
Sorted by citations
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,266
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 905
Metadata
- Authors
- Ferris, R. L., Jaffee, E. M., & Ferrone, S.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-01
- Volume
- 28
- Issue
- 28
- Pages
- 4390-4399
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2954137
- OpenAlex
- W2112887207
- Cited by
- 320
- References
- 122
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- American Society of Clinical Oncology
- National Cancer Institute (P50CA097190)
- National Institute of Dental and Craniofacial Research (R01DE019727)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
